Bayer is defending its $7.25 billion Roundup settlement because the alternative—facing an unlimited wave of litigation with unpredictable verdicts and jury sympathy toward cancer plaintiffs—is far riskier financially. The company has already spent over $10 billion resolving previous Roundup lawsuits, with approximately 65,000 claims still pending. The latest settlement, announced February 17, 2026, offers something Bayer desperately needs: a defined endpoint to current and future claims over a 21-year period, preventing the slow bleed of billion-dollar verdicts that could extend indefinitely. Beyond financial protection, Bayer is using this settlement as part of a broader legal strategy.
While accepting the $7.25 billion payout, Bayer is simultaneously defending its product in federal court—most notably in oral arguments scheduled for April 27, 2026, before the Supreme Court in the case *Durnell v. Monsanto*. This case challenges whether state courts even have the right to hear Roundup cancer claims, arguing that federal pesticide law preempts such lawsuits. In other words, Bayer is betting that by containing current litigation through settlement, it can establish a legal precedent that prevents this entire category of lawsuits from being filed in the future.
Table of Contents
- Why Settlement Makes Financial Sense Despite the Massive Payout
- The Supreme Court Gamble—A Parallel Defense Strategy
- The Unresolved Claims Problem—Why 65,000 Cases Still Matter
- The Precedent of Previous Verdicts—Understanding What Bayer Is Avoiding
- The Admission That Isn’t—Defending Without Admitting Liability
- The Scientific and Regulatory Dispute Underpinning Everything
- What Comes Next—The Supreme Court Decision and Beyond
- Conclusion
Why Settlement Makes Financial Sense Despite the Massive Payout
Paying $7.25 billion sounds staggering until you compare it to the alternative: a continuing cycle of jury trials where bayer loses consistently. In May 2025, a Missouri appellate court affirmed a $611 million verdict against Monsanto in a single Roundup case. A $1.25 million verdict from a 2023 Missouri jury is currently appealing to the Supreme Court. These aren’t outliers—they represent a pattern of litigation costs that accumulate rapidly. The settlement fund, spread across 21 years, is anchored by an $8 billion loan facility that Bayer has already secured to fund payouts.
This structure allows Bayer to budget for the expenses rather than face surprise jury verdicts that crater quarterly earnings. When a company has already accumulated €11.8 billion in litigation reserves (with €9.6 billion specifically earmarked for glyphosate litigation), as Bayer has, settling becomes the less chaotic path. The company also avoids the unpredictable costs of discovery, expert witnesses, and appeals—costs that can rival the settlement itself when multiplied across 65,000 individual cases. However, this math changes dramatically if the Supreme Court rules in Bayer’s favor on preemption. If federal law preempts state-level failure-to-warn claims, then future Roundup lawsuits could be blocked at the courthouse door, making the settlement retroactively look like an overpayment. But Bayer cannot count on that outcome, so it’s hedging by settling the known liability while fighting for legal precedent in court.
The Supreme Court Gamble—A Parallel Defense Strategy
What makes Bayer’s position unusual is that it’s simultaneously accepting a massive settlement *and* arguing in federal court that it shouldn’t have to settle at all. The Supreme Court case *Durnell v. Monsanto*, with oral arguments scheduled for April 27, 2026, centers on whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) preempts state-level lawsuits alleging that Roundup’s label failed to warn of cancer risks. Bayer’s argument is straightforward: the EPA, the federal agency responsible for regulating pesticides, has reviewed glyphosate (Roundup’s active ingredient) and determined it does not cause cancer. The EPA’s most recent position, reflected in current regulatory guidance, states that glyphosate-based herbicides do not pose a cancer risk and do not require a warning label.
If federal law has already been applied to this product, Bayer argues, then state juries shouldn’t be allowed to second-guess the EPA’s decision and impose warning labels through litigation. This legal theory, if accepted by the Supreme Court, would be transformative—not just for Bayer, but for the entire pesticide and pharmaceutical industry. A preemption ruling would mean that once the EPA approves a product label, state courts cannot force manufacturers to add warnings that contradict federal determinations. The catch: the Supreme Court has rejected similar preemption arguments in the past, and plaintiffs’ attorneys will present the counter-argument that companies can still be liable for fraud, misrepresentation, or failure to update labels when new evidence emerges. Bayer cannot count on a Supreme Court win, which is why the settlement provides insurance.
The Unresolved Claims Problem—Why 65,000 Cases Still Matter
Even if Bayer wanted to walk away from all Roundup litigation, it can’t. Approximately 65,000 claims are still pending against the company, and many of those claimants haven’t signed onto the settlement agreement. When preliminary court approval was granted on March 4, 2026, the judge set a deadline of June 4, 2026, for class members to decide whether to opt out of the settlement and pursue their own lawsuits instead. This opt-out window is crucial to Bayer’s strategy. Any plaintiff who believes they have a stronger individual case—or who distrusts class settlements—can reject the deal and file their own lawsuit. For Bayer, this means the settlement doesn’t eliminate litigation risk; it only converts unquantified risk into a fixed cost.
If 10,000 claimants opt out and pursue individual cases, Bayer could face another decade of trial costs and verdicts. If only 1,000 opt out, the math improves. The company is defending the settlement partly because it’s the best predictable outcome given the opt-out uncertainty. The fairness hearing is scheduled for July 9, 2026, when the Missouri judge will decide whether to grant final approval. Between now and then, plaintiffs’ attorneys will mobilize to convince clients to reject the settlement, arguing they can do better individually. Bayer’s defense of the settlement is also an implicit acknowledgment that some litigation will continue no matter what, and that a structured end date is better than an indefinite legal war.
The Precedent of Previous Verdicts—Understanding What Bayer Is Avoiding
To understand why Bayer is willing to pay $7.25 billion, it helps to examine what it’s already paid and what juries have awarded. The $611 million verdict affirmed in May 2025 represents a single plaintiff or small group of plaintiffs. Multiply that across even a fraction of 65,000 claims, and the math becomes catastrophic for an individual-trials approach. Bayer has also achieved some courtroom wins. In the Shelton trial, a jury determined that Roundup did not cause the plaintiff’s cancer, resulting in an acquittal for Monsanto.
However, these wins don’t offset the losses. Plaintiffs’ lawyers have demonstrated they can convince juries that Roundup poses a cancer risk, despite EPA approval and Bayer’s contrary evidence. This inconsistency—some juries finding liability, some finding none—is exactly the unpredictability that settlements are designed to eliminate. The settlement becomes Bayer’s way of saying: “We’ve calculated that paying a fixed amount is less damaging than continuing to play lawsuit roulette.” Some claimants will receive less in settlement than they might win at trial; others will receive more. The distribution is uncertain, which is why the July 9 fairness hearing is critical—the judge must determine whether the settlement terms are reasonable given what plaintiffs might expect to win if they litigated individually.
The Admission That Isn’t—Defending Without Admitting Liability
One of the most legally significant aspects of Bayer’s defense is that the company is *not admitting liability* in the settlement. Bayer continues to maintain that glyphosate does not cause cancer, despite agreeing to pay billions to settle claims alleging exactly that. This creates a paradox that plaintiffs’ attorneys regularly exploit in fairness hearings: “If Roundup is safe, why is Bayer paying to compensate people allegedly harmed by it?” Bayer’s answer is that settlement is not an admission of liability—it’s a business decision made in the face of uncertain jury outcomes and unlimited litigation costs.
This position is legally defensible under settlement doctrine, but it raises a complication. If Bayer is settling without admitting that Roundup causes cancer, then its defense of the settlement rests heavily on the preemption argument. If the Supreme Court rules that FIFRA preempts state failure-to-warn claims, Bayer’s position strengthens retroactively: “We settled to eliminate uncertainty, and it turned out we were right all along.” However, if the Supreme Court rejects preemption, Bayer will have paid $7.25 billion to resolve claims that it simultaneously denies having merit. This is not uncommon in major settlements, but it does explain why Bayer is simultaneously defending the settlement (it’s necessary) and defending glyphosate’s safety in federal court (it’s the long-term strategy).
The Scientific and Regulatory Dispute Underpinning Everything
The root of Bayer’s defense strategy lies in a fundamental scientific disagreement. The EPA, the most recent authoritative voice on pesticide safety in the United States, has stated that glyphosate does not cause cancer and does not require warning labels based on carcinogenicity. The International Agency for Research on Cancer (IARC), a division of the World Health Organization, classified glyphosate as “probably carcinogenic to humans” in 2015, but this classification does not carry regulatory weight in the United States.
Bayer’s position—that its product is safe and that federal regulators agree—is technically correct based on EPA determinations. But juries across the country have rejected this official position and sided with cancer patients alleging Roundup exposure caused their illness. This disconnect between regulatory approval and jury verdicts is the core of Bayer’s legal and public relations problem, and it explains why the company is pursuing preemption at the Supreme Court level rather than simply accepting the new litigation reality.
What Comes Next—The Supreme Court Decision and Beyond
The Supreme Court’s decision in *Durnell v. Monsanto*, expected sometime in 2027, will shape whether Bayer’s settlement strategy was sufficient or if future Roundup claimants find new avenues for litigation. If preemption prevails, Bayer wins retroactively. If preemption loses, the company’s litigation reserves may need to grow further, but at least the settlement provides a known cap on current and future claims.
Bayer is also watching international regulators. While the EPA has reaffirmed glyphosate’s safety, some countries have restricted or banned glyphosate-based herbicides. If more jurisdictions move toward precaution, Bayer’s long-term Roundup business faces structural challenges regardless of the litigation outcome. The settlement, from this perspective, also buys Bayer time to manage its portfolio transition away from Roundup and toward alternative herbicides.
Conclusion
Bayer is defending its $7.25 billion Roundup settlement because it represents the most predictable outcome in an inherently unpredictable legal landscape. The company has already spent $10 billion on previous settlements and verdicts, and 65,000 claims remain pending. By establishing a 21-year cap on liability, Bayer trades the certainty of a massive known cost for the uncertainty of unlimited jury trials and indefinite appeals. Simultaneously, the company is betting on a Supreme Court preemption victory that could block future Roundup claims entirely—a gamble that provides additional justification for settling now.
For claimants weighing whether to accept the settlement by the June 4, 2026 opt-out deadline, the key is understanding that Bayer’s defense of the deal does not mean the company believes its product is safe or that claimants lack merit. Rather, it reflects Bayer’s calculation that paying now is less expensive and disruptive than litigating forever. The July 9 fairness hearing will provide more information about how individual settlement awards are calculated and whether the global fund is adequate. Claimants should consult with attorneys to determine whether the settlement terms meet their individual circumstances or whether opting out to pursue separate litigation is advisable.